Nutromics received an FDA breakthrough device designation for its wearable patch intended to monitor vancomycin levels in real time. The company’s system is designed to replace periodic blood draws used to dose the antibiotic, addressing the practical challenge of therapeutic drug monitoring for a medication with narrow dosing windows. The designation signals FDA receptiveness to digital health-adjacent monitoring tools that can reduce clinician workflow burden while improving dosing accuracy for patients requiring vancomycin.